Nechaev D D, Bochko I I, Kuz'mina L F, Martynov I V, Khloponina N N
Ter Arkh. 1987;59(10):105-8.
A study was made of the effect of moderate (300-500 units/kg per day) and minimum (200-250 units/kg per day) heparin doses in intravenous drop administration on the coagulation and thrombocytic links of hemostasis in 26 elderly and advanced age patients with myocardial infarction. The patients were divided into 2 groups: streptodecase and heparin were administered to the patients of the 1st group and heparin only was administered to the patients of the 2nd group. No significant effect of streptodecase on the hemocoagulation link of hemostasis with a low risk of developing hemorrhagic complications was noted. In 72-96 h of treatment intravenous heparin administration resulted in a decrease in a level of blood antithrombin III causing a decrease in the efficacy of heparin therapy. Control over a level of blood antithrombin III in addition to routine tests (thrombin time, thromboelastogram) provided an opportunity for adequate anticoagulant therapy. A negative effect of heparin on the thrombocytic link of hemostasis with deterioration of disaggregation properties and an increase in aggregation was noted. Antiaggregation therapy in parallel with the start of heparin administration was found necessary.
对26例老年及高龄心肌梗死患者静脉滴注中等剂量(每天300 - 500单位/千克)和最小剂量(每天200 - 250单位/千克)肝素对止血的凝血和血小板环节的影响进行了研究。患者分为2组:第1组患者给予链激酶和肝素,第2组患者仅给予肝素。未观察到链激酶对止血的血液凝固环节有显著影响,且出血并发症发生风险较低。在治疗72 - 96小时时,静脉注射肝素导致血液抗凝血酶III水平降低,从而使肝素治疗效果下降。除常规检查(凝血酶时间、血栓弹力图)外,监测血液抗凝血酶III水平为进行充分的抗凝治疗提供了机会。观察到肝素对止血的血小板环节有负面影响,表现为解聚特性恶化和聚集增加。发现与开始肝素治疗同时进行抗聚集治疗是必要的。